
Adjuvant Pertuzumab Shows OS Benefit in Breast Cancer
Adding adjuvant pertuzumab to standard adjuvant chemotherapy and trastuzumab improved overall survival at 11 years of follow-up in patients with early human epidermal growth factor receptor 2 (HER2)–positive operable breast cancer, according to a new …